Natural killer group 2 member D–ligand complex (NKG2D–ligand complex)

The Natural Killer Group 2 Member D (NKG2D)–ligand complex is a pivotal immune signaling unit composed of the NKG2D receptor (encoded by KLRK1) and its various stress-induced ligands, such as MICA, MICB, and the ULBP family (UniProt: P26712). NKG2D is a type II transmembrane protein expressed as a homodimer on the surface of natural killer (NK) cells, CD8+ T cells, and γδ T cells, where it functions as a primary activating receptor (PubMed: 11777960). Its ligands are typically absent from healthy tissues but are upregulated during viral infection, malignant transformation, or oxidative stress, acting as "eat-me" signals for the immune system (PubMed: 21149606). Binding of these ligands to NKG2D triggers potent cytotoxic responses and cytokine production, facilitating the clearance of abnormal cells. In cancer, tumors often evade this system by shedding surface ligands into a soluble form that desensitizes the receptor, making the stabilization of these ligands a key therapeutic goal (PubMed: 29590618). Conversely, in autoimmune diseases like Crohn's disease and rheumatoid arthritis, the NKG2D–ligand axis is chronically overactive, leading to pathological tissue damage (PubMed: 24323353). Therapeutic interventions include monoclonal antibodies to block the axis in inflammatory conditions or bispecific engagers and CAR-based therapies to harness the complex for anti-tumor immunity (ClinicalTrials.gov: NCT02599441). This complex represents a unique stress-sensing mechanism that bridges innate and adaptive immunity.

Other names

KLRK1–ligand complexCD314–ligand complexNKG2D–MICA/B complexNKG2D–ULBP complexNKG2D receptor–ligand axis

Antagonism of the NKG2D receptor to suppress inflammatory cytokine production and cytotoxicity in autoimmune diseases; Monoclonal antibody-mediated stabilization of surface MICA/B ligands to prevent proteolytic shedding and restore immune recognition in cancer; Chimeric antigen receptor (CAR) expression using the NKG2D extracellular domain to redirect T or NK cells toward ligand-expressing tumor cells (PubMed: 29590618, PubMed: 24323353).